Suppr超能文献

血管内治疗联合免疫抑制治疗白塞病患者的假性动脉瘤

Endovascular therapy combined with immunosuppressive treatment for pseudoaneurysms in patients with Behçet's disease.

作者信息

Kwon Koo Bon, Shim Won-Heum, Yoon Young-Sup, Kwon Lee Byoung, Choi Donghoon, Jang Yangsoo, Lee Do-Yun, Chang Byung-Chul

机构信息

Division of Cardiology, Yonsei Cardiovascular Center and Cardiovascular Research Institute, Seoul, Korea.

出版信息

J Endovasc Ther. 2003 Feb;10(1):75-80. doi: 10.1177/152660280301000116.

Abstract

PURPOSE

To evaluate the feasibility, efficacy, and outcome of endovascular therapy combined with immunosuppression for the treatment of arterial pseudoaneurysms due to Behçet's disease.

METHODS

Eleven pseudoaneurysms (3 in the abdominal aorta, 3 in the subclavian artery, and individual lesions in the brachiocephalic artery, renal artery, common iliac artery, common carotid artery, and the descending thoracic aorta) in 9 patients with Behçet's disease were treated with 10 stent-grafts and 1 self-expanding stent. All patients with elevated erythrocyte sedimentation rate (ESR) were treated with immunosuppressive agents (azathioprine, prednisolone) before and after the procedure.

RESULTS

Endovascular treatment was successful in all cases, without major adverse events. The ESR was reduced from 42.7+/-18.0 mm/h initially to 18.6+/-12.6 mm/h after immunosuppressive therapy prior to endovascular repair. During follow-up (mean 24.1+/-14.0 months, range 6-43), 8 of 11 lesions showed complete resolution. One stent-graft to treat a postsurgical recurrent carotid artery pseudoaneurysm was occluded, and an abdominal aortic pseudoaneurysm recurred; both patients stopped their medications. ESR during follow-up was 7.9+/-4.5 mm/h.

CONCLUSIONS

Endovascular treatment for pseudoaneurysms due to Behçet's disease is feasible and effective when disease activity is strictly controlled with immunosuppressive therapy.

摘要

目的

评估血管内治疗联合免疫抑制疗法治疗白塞病所致动脉假性动脉瘤的可行性、疗效及预后。

方法

9例白塞病患者的11个假性动脉瘤(腹主动脉3个、锁骨下动脉3个,头臂干动脉、肾动脉、髂总动脉、颈总动脉及胸降主动脉各1个)接受了10枚覆膜支架和1枚自膨式支架治疗。所有红细胞沉降率(ESR)升高的患者在手术前后均接受免疫抑制剂(硫唑嘌呤、泼尼松龙)治疗。

结果

所有病例血管内治疗均成功,无严重不良事件。血管内修复术前免疫抑制治疗后,ESR从最初的42.7±18.0mm/h降至18.6±12.6mm/h。随访期间(平均24.1±14.0个月,范围6 - 43个月),11个病变中的8个完全消退。1枚用于治疗术后复发性颈总动脉假性动脉瘤的覆膜支架闭塞,1例腹主动脉假性动脉瘤复发;这2例患者均停药。随访期间ESR为7.9±4.5mm/h。

结论

当通过免疫抑制疗法严格控制疾病活动时,血管内治疗白塞病所致假性动脉瘤是可行且有效的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验